| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
15,080,000 |
| Market
Cap: |
22.77(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.42 - $2.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cumberland Pharmaceuticals is a pharmaceutical company engaged on the acquisition, development and commercialization of prescription products. Co.'s portfolio of brands include: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for the treatment of constipation; Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; and Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
27,346 |
| Total Buy Value |
$0 |
$0 |
$0 |
$63,218 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
444 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Krogulski Kenneth |
Director |
– • – |
2021-12-16 |
4 |
AB |
$4.53 |
$1,087 |
D/D |
240 |
182,625 |
|
-42% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-12-16 |
4 |
AB |
$4.53 |
$227 |
D/D |
50 |
5,770,453 |
|
-42% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-12-16 |
4 |
AB |
$4.53 |
$1,087 |
D/D |
240 |
177,919 |
|
-42% |
|
| Jones James |
Director |
– • – |
2021-12-15 |
4 |
AB |
$4.29 |
$129 |
D/D |
30 |
19,200 |
|
-53% |
|
| Young Caroline |
Director |
– • – |
2021-12-15 |
4 |
AB |
$4.29 |
$129 |
D/D |
30 |
14,617 |
|
-53% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-12-15 |
4 |
AB |
$4.29 |
$858 |
D/D |
200 |
182,385 |
|
-53% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-12-15 |
4 |
AB |
$4.29 |
$129 |
D/D |
30 |
5,770,403 |
|
-53% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-12-15 |
4 |
AB |
$4.29 |
$858 |
D/D |
200 |
177,679 |
|
-53% |
|
| Jones James |
Director |
– • – |
2021-12-14 |
4 |
AB |
$4.28 |
$128 |
D/D |
30 |
19,170 |
|
-42% |
|
| Young Caroline |
Director |
– • – |
2021-12-14 |
4 |
AB |
$4.28 |
$128 |
D/D |
30 |
14,587 |
|
-42% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-12-14 |
4 |
AB |
$4.28 |
$856 |
D/D |
200 |
182,185 |
|
-42% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-12-14 |
4 |
AB |
$4.28 |
$128 |
D/D |
30 |
5,770,373 |
|
-42% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-12-14 |
4 |
AB |
$4.28 |
$856 |
D/D |
200 |
177,479 |
|
-42% |
|
| Jones James |
Director |
– • – |
2021-12-13 |
4 |
AB |
$4.36 |
$131 |
D/D |
30 |
19,140 |
|
-39% |
|
| Young Caroline |
Director |
– • – |
2021-12-13 |
4 |
AB |
$4.36 |
$131 |
D/D |
30 |
14,557 |
|
-39% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-12-13 |
4 |
AB |
$4.36 |
$872 |
D/D |
200 |
181,985 |
|
-39% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-12-13 |
4 |
AB |
$4.36 |
$131 |
D/D |
30 |
5,770,343 |
|
-39% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-12-13 |
4 |
AB |
$4.36 |
$872 |
D/D |
200 |
177,279 |
|
-39% |
|
| Jones James |
Director |
– • – |
2021-12-10 |
4 |
AB |
$4.82 |
$101 |
D/D |
21 |
19,110 |
|
-42% |
|
| Young Caroline |
Director |
– • – |
2021-12-10 |
4 |
AB |
$4.82 |
$87 |
D/D |
18 |
14,527 |
|
-42% |
|
| Krogulski Kenneth |
Director |
– • – |
2021-12-10 |
4 |
AB |
$4.82 |
$362 |
D/D |
75 |
181,785 |
|
-42% |
|
| Kazimi A J |
Chairman and CEO |
• • • |
2021-12-10 |
4 |
AB |
$4.82 |
$87 |
D/D |
18 |
5,770,313 |
|
-42% |
|
| Cearnal Martin E |
Sr VP/Chief Commercial Officer |
• • – |
2021-12-10 |
4 |
AB |
$4.82 |
$434 |
D/D |
90 |
177,079 |
|
-42% |
|
| Jones James |
Director |
– • – |
2021-12-09 |
4 |
AB |
$5.81 |
$122 |
D/D |
21 |
19,089 |
|
-44% |
|
| Young Caroline |
Director |
– • – |
2021-12-09 |
4 |
AB |
$5.81 |
$105 |
D/D |
18 |
14,509 |
|
-44% |
|
1400 Records found
|
|
Page 22 of 56 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.67%) 
